E-submission
Search
- Page Path
- HOME > Search
Original Article
- HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
- Dang Anh Thu Phan, Vu Thien Nguyen, Thi Ngoc Ha Hua, Quoc Dat Ngo, Thi Phuong Thao Doan, Sao Trung Nguyen, Anh Tu Thai, Van Thanh Nguyen
- J Pathol Transl Med. 2017;51(4):396-402. Published online June 19, 2017
- DOI: https://doi.org/10.4132/jptm.2017.04.24
- 7,995 View
- 139 Download
- 8 Web of Science
- 7 Crossref
-
Abstract
PDF - Background
Human epidermal growth factor receptor 2 (HER2) is related to the pathogenesis and poor outcome of numerous types of carcinomas, including gastric carcinoma. Gastric cancer patients with HER2 positivity have become potential candidates for targeted therapy with trastuzumab.
Methods
We investigated 208 gastric cancer specimens using immunohistochemistry (IHC), fluorescence in situ hybridization and dual in situ hybridization (ISH). We also investigated the concordance between IHC and ISH. The correlation between HER2 status and various clinicopathological findings was also investigated.
Results
In total, 15.9% (33/208) and 24.5% (51/208) of gastric cancers showed HER2 gene amplification and protein overexpression, respectively. A high level of concordance between ISH and IHC analyses (91.3%, κ = 0.76) was found. A significant correlation between HER2 status and intestinal-type (p < .05) and differentiated carcinomas (p < .05) was also noted. The HER2 heterogeneity was high in gastric cancers; we found 68.8% phenotypic heterogeneity and 57.6% genotypic heterogeneity. Heterogeneity in HER2 protein expression and gene amplification showed a close association with diffuse histologic type and IHC 2+.
Conclusions
HER2 protein overexpression and gene amplification were detected in 24.5% and 15.9% of gastric cancer specimens, respectively. Intestinal-type showed a higher level of HER2 protein overexpression and gene amplification than diffuse type. HER2 status also showed a significant relationship with well- and moderately-differentiated carcinomas. The ratio of phenotypic and genotypic heterogeneity of HER2 was high in gastric carcinomas and was associated with HER2 IHC 2+ and diffuse histologic type. -
Citations
Citations to this article as recorded by
- Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy
Qian Li, Minzhi Lv, Lihua Lv, Nida Cao, Aiguang Zhao, Jiayan Chen, Xi Tang, Rongkui Luo, Shan Yu, Yan Zhou, Yuehong Cui, Wei Guo, Tianshu Liu
Cancer Medicine.2023; 12(4): 4110. CrossRef - A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma
Rafid A. Abood, Saad Alomar, Sawsan S. Alharoon
Journal of Public Health in Africa.2023;[Epub] CrossRef - Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
Hideki Yamaguchi, Yuko Nagamura, Makoto Miyazaki
Cancers.2022; 14(15): 3750. CrossRef - Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer
Renshen Xiang, Yuping Rong, Yuhang Ge, Wei Song, Jun Ren, Tao Fu
Aging.2021; 13(4): 5928. CrossRef - Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling
Renshen Xiang, Wei Song, Jun Ren, Jing Wu, Jincheng Fu, Tao Fu
Stem Cell Research & Therapy.2021;[Epub] CrossRef - Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
Yoshie Kobayashi, Seung-Oe Lim, Hirohito Yamaguchi
Seminars in Cancer Biology.2020; 65: 51. CrossRef - Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer
Yu-Chang Chuang, Hsin-Yi Wu, Yu-Ling Lin, Shey-Cherng Tzou, Cheng-Hsun Chuang, Ting-Yan Jian, Pin-Rong Chen, Yuan-Ching Chang, Chi-Hsin Lin, Tse-Hung Huang, Chao-Ching Wang, Yi-Lin Chan, Kuang-Wen Liao
Biological Procedures Online.2018;[Epub] CrossRef
- Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy
First
Prev
